Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial involving fianlimab and Libtayo. In March 2026, Regeneron's investor relations VP expressed optimism about the trial's outcomes, but in May 2026, the company disclosed the trial failed to meet its primary endpoint, causing a sharp stock decline. The investigation aims to determine if Regeneron violated federal securities laws by not adequately disclosing risks. Investors who suffered losses may seek recovery through legal channels.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
Pomerantz LLP is investigating Regeneron Pharmaceuticals for potential securities fraud following the company's announcement that a Phase 3 trial for its cancer drug combo failed to meet key goals. The trial results, disclosed on May 15, 2026, showed...
Regeneron Pharmaceuticals is rated a Buy due to strong growth in its EYLEA HD product, which saw U.S. sales increase by 52% in Q1 2026, offsetting competition and patient switching. The company also benefits from robust growth of DUPIXENT and a diver...
